Omnicare Inc

Omnicare — Q1 2014 Earnings Presentation

16 slides from Omnicare's earnings presentation, Apr 23, 2014

  1. Slide 1: Omnicare

    Omnicare

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain of mace lovey it i the following re fe ‘d-lookir i i vate ities Litigation Reform Act of 1995. These forward-| Hooking statements include, but are not tte to, all statements ir ue intent, belief or Current regarding Such and involve k and orleaan risks, uncertainti

  3. Slide 3: Table of Contents

    _ Appendix. _ Gross Profit & Adjusted Operating Income. Table of Contents Rirst-Quarter 2014-HIQhliQht vsscsccsssssessecconass va ves reusersasareren cassssseesearbetes Operating Metrics — Script Data Adjusted Net Income & Cash EPS....... Adjusted Operating Income by Segment Cash Flows — Cash Deploy

  4. Slide 4: First-Quarter 2014 Highlights

    First-Quarter 2014 Highlights) Revenue of $1,571M; 7.7% year-over-year increase Gross profit of $358.5M; gross margin of 22.8% Adjusted EBITDA of $177.7M; 10.4% year-over-year increase Adjusted operating income of $150.1M; 11.2% year-over-year increase Adjusted cash earnings per diluted share of $0.

  5. Slide 5: Operating Metrics - Script Data

    1 B Operating Metrics Script Data” Sequential Prior Year Increase / Increase / (In thousands, except %s) 1Q2014 _4Q2013 (Decrease) 102013 (Decrease) Long-Term Care Group Scripts: Generic scripts dispensed 20,853 20,404 2.2% 20,672 0.9% Branded scripts dispensed 4,107 4,215 (2.6%) 4,297 (4.4%) Over-t

  6. Slide 6: Gross Profit & Adjusted Operating Income

    Gross Profit & Adjusted Operating Income )2) Sequential Prior Year Increase / Increase / In millions, except per share data and %s 1Q2014 _4Q2013 (Decrease) 12013 (Decrease) Net sales $1,571.0 $1,536.2 2.3% $ 1,458.9 7.7% Cost of sales 4,212.6 1,176.5 3.1% 1,109.2 9.3% Gross profit $358.5 $ 359.7 (0

  7. Slide 7: Adjusted Net Income & Cash EPS

    Adjusted Net Income & Cash EPS) Sequential Prior Year Increase / Increase / In millions, except per share data and %s 10.2014 42013 (Decrease) _1@2013 (Decrease) i $ 150.1 $ 144, 4.0% 135.0 11.2% Adjusted interest expense, net of investment income (23.3) (23.8) (2.1%) (23.4) (0.4%) Adjusted income b

  8. Slide 8: Adjusted Operating Income by Segment

    Adjusted Operating Income by Segment “) Sequential Increase / Increase / 1Q2014 402013 (Decrease) _1Q13 (Decrease) is pai except % m Care Group Eee $ 1,191.3 $ 1,169.1 2% $F 1,141.6 4% palsies ‘operating income®) 162.1 160.4 1% 155.2 % Rate 13.61% 13.72% -11 bps 13.59% 2 bps In whole numbers Per scr

  9. Slide 9: Cash Flows

    Cash Flows “) Sequential Prior Year Increase / Increase / 10.2014 402013 (Decrease) 102013 (Decrease! Net income / (Loss) $ 638 $ (637) (176.2%) $ 17.3% (Income) / Loss from discontinued operations $ (0.1) $ 1423 (100.1%) $ (6.0) (98.3%) Adjustments to reconcile net income to net cash flows from ope

  10. Slide 10: Cash Deployment

    Cash Deployment Sequential Prior Year Increase / Increase / In millions, except %s 1Q2014 _4Q2013_ (Decrease) _1@2013_ (Decrease) Net cash flows from operating activities of continuing operations (reported) $ 1716 $ 235 630.2% $ 106.5 61.1% Capital expenditures 26.2 217 20.7% 22.4 17.0% Acauisitions

  11. Slide 11: Full-Year 2014 Guidance

    1 B a i Full-Year 2014 Guidance Fs Previous Guidance | Current Guidance®) - Net sales $6.3B to $6.4B » Adjusted cash earnings per diluted share from continuing operations® BOER OVS. * Cash flow from continuing eperations iA $475M to $550M $6.3B to $6.4B $3.64 to $3.72 $475M to $550M ‘Guidance provid

  12. Slide 12: Appendix

    RNY ly, “yg; Omnicare Appendix

  13. Slide 13: Capital Structure

    Capital Structure Major Debt Maturity Schedule“) {in § millions) $1,800 @As of 9/30/10 mAs of 3/31/14 $1,500 $1,200 $900 $600 $300 | | .! I 2010 2015 2020 2025 2030 2035 2045 Continue to focus on leveraging our strong balance sheet to spread out and lower ig costs dates 1s 033, 014 E+) Omnicare mes

  14. Slide 14: Working Capital Management

    Working Capital Management Five Quarter Trend() Days of Inventory On Hand (DOH) a 8 44.5 10 42.9 43.3 & Days Sales Outstanding (DSO) 1013 2Q13 3a13 4ai3 1014 Inventories declined as expected following certain inventory purchasing initiatives in 4Q13 DDOH= Ending Imenay (Quartery Cost of Sales /Daysi

  15. Slide 15: Selected Branded Drug Patent Expirations

    Selected Branded Drug Patent Expirations'”) 2014 2015 Abilify Renagel Aggrenox Renvela ‘Avodart Cellcept (Sol.) Celebrex Mytortic Transderm-Seop Copaxone Micardis IR Diovan IR Epivir- HBV Tabs 2014 Gleevec nel Namenda IR Nexium (Caps) Oxytrol - Patanol Evista 3Q14 Travatan Z Lovaza Invega ER Welchol

  16. Slide 16: Omnicare

    Omnicare

Omnicare — Q1 2014 Earnings Presentation on 6ix